Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

AVLN

Avalyn Pharma Inc

May 06 • 04:00PM ET

27.71

+0.28 1.02 %

Healthcare • Biotechnology • USA • Small • NASD

Held by: TMSL TMED TNXT

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	41.81M	Perf Week	-
Market Cap	1.16B	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	41.81M	Perf Month	-
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf YTD	-6.04%
Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W High	30.67 -9.65%	Perf Year	-
Cash/sh	-	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	25.44 8.92%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	- -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	3.25	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	-	EPS Q/Q	-	SMA20	-3.48%	Beta	-	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-3.48%	Rel Volume	0.32	Prev Close	27.43
Employees	50	LT Debt/Eq	-	Earnings	-	SMA200	-3.48%	Avg Volume	1.77M	Price	27.71
IPO	Apr 30, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	673,816	Change	1.02%

May-05-26 04:01PM	Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference (GlobeNewswire) -5.64%
May-01-26 04:01PM	Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)

Avalyn Pharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). The company was founded by Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar on May 27, 2011 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novo Holdings A/S	10% Owner	May 01 '26	Buy	18.00	555,555	9,999,990	3,883,289	May 05 04:15 PM
Carroll Jill	Director	May 01 '26	Buy	18.00	277,778	5,000,004	2,186,562	May 01 06:50 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	May 01 '26	Buy	18.00	555,555	9,999,990	2,186,562	May 01 06:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVLN

Avalyn Pharma Inc

Upgrade your Finviz experience